SCHEMBL23380262

SCHEMBL23380262

CC(C)c1cccc(-c2c(F)cc(CC(=O)O)cc2F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRA P10827 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ RXRA P19793 2/20 0.48
▸ RXRB P28702 1/20 0.48
▸ RXRG P48443 1/20 0.48
▸ PTPN5 P54829 2/20 0.43
▸ PPARG P37231 1/20 0.41
▸ FFAR1 O14842 1/20 0.40
▸ CFD P00746 1/20 0.40
▸ F11 P03951 1/20 0.40
▸ TPSB2 P20231 1/20 0.40
▸ PTGS1 P23219 4/20 0.40
▸ AKR1C3 P42330 3/20 0.40
▸ AKR1C2 P52895 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ PTGS2 P35354 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ FABP2 P12104 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25598440 0.83 FFAR1 (0.53) THRATHRBRXRARXRBRXRG
SCHEMBL25617585 0.81 AKR1C3 (0.47) PPARGFFAR1PTGS1AKR1C3AKR1C2
SCHEMBL23380676 0.81 RXRA (0.63) RXRARXRBRXRGPTPN5PTGS1
SCHEMBL13524596 0.80 RXRA (0.65) THRATHRBRXRARXRBRXRG
SCHEMBL26816793 0.78 RXRA (0.51) RXRARXRBRXRGPTPN5PTGS1
SCHEMBL1261429 0.77 AKR1B1 (0.52) THRATHRBRXRARXRBRXRG
SCHEMBL23380269 0.76 RXRA (0.46) RXRARXRBRXRGPTPN5PTGS1
SCHEMBL26816807 0.73 PTPN5 (0.44) RXRARXRBRXRGPTPN5PTGS1
SCHEMBL23380677 0.72 RXRA (0.55) RXRARXRBRXRGPTPN5PTGS1
SCHEMBL26816810 0.72 FFAR1 (0.40) RXRARXRBRXRGPTPN5FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357214-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) 2023-11-09 — — US disclosed
US-20230357214-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) 2023-11-09 — — US disclosed
US-20210147398-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY PHENEX-FXR GMBH (DE) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147398-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY NR1H2, NR1H3, NR1H4 THRA 541/4885THRB 165/4885RXRA 26/4885
US-20230357214-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY NR1H2, NR1H3, NR1H4 THRA 541/4885THRB 165/4885RXRA 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback